在威尔逊病的铁和铜肝度
Patrick Lloyd Day1, Ria Fyffe-Freil2, Patrick Vanderboom3
1Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. day.patrick@mayo.edu.
Journal of gastrointestinal and liver diseases : JGLD
|December 29, 2024
概括
这项研究发现,怀疑威尔逊病 (WD) 的8%的患者表现出二次铁过载的迹象. 低血红蛋白和血红素水平也与确诊的WD病例中肝脏铜度较高有关.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 代谢障碍 代谢障碍 代谢障碍
- 遗传疾病 遗传疾病
背景情况:
- 威尔逊病 (WD) 涉及铜代谢受损,导致铜在肝脏等器官中的积累.
- 二次铁过载是WD的潜在并发症,但其患病率尚未确立.
- 了解WD中铁过载和贫血对于患者管理至关重要.
研究的目的:
- 为了确定怀疑威尔逊病的患者中二次铁过载的患病率.
- 为了研究常见的实验室测试和肝铜度或确认WD患者的移植需求之间的关联.
主要方法:
- 对197名肝铜度升高的患者 (>250微克/克) 和可用的肝铁度数据的回顾性分析.
- 铜,铁和肝脏铁指数的统计相关性分析 (皮尔森方法).
- 对10名确诊的WD患者的实验室测试值的评估,以确定与肝铜或移植的关联.
主要成果:
- 肝脏铜和铁度之间没有发现显著的相关性 (p=0.84).
- 肝脏铁指数>1.0,表明潜在的铁过载,在8% (13/197) 的13岁及以上的患者中观察到.
- 在确诊的WD患者中,血红蛋白和血红素与肝铜度相反相关 (p=0.036).
结论:
- 在患有威尔逊病的患者的肝脏组织中可以检测到二次铁过载.
- 低血红蛋白和血红素水平与WD患者肝铜升高有关.
- 临床医生应考虑对被诊断患有威尔逊病的患者进行二次铁过载和贫血的查.
更多相关视频
11:04Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides
Published on: September 7, 2019
9.1K
05:08Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay
Published on: January 31, 2022
4.3K
相关概念视频
00:56Extraction: Advanced Methods
386
Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is...
386
01:30Liver Physiology
372
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
372
01:26Diseases of the Liver and Gallbladder
328
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
328